Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > AD reading

<< Previous

Bullboard Posts

Next >>

Comment by Lookingforclueson Jun 23, 2021 10:00pm

95 Views

Post# 33439429

RE:AD reading

MrMugsy wrote: Just a little reading material for those inclined to have a look.

Makes sense as a potential way to improve brain cell modulation and lead to cellular protection and repair.

Our partner is talking about it regularly - even in a call today.
Can't wait to see if it goes anywhere - with or without Exelon as the active ingredient.

https://www.pnas.org/content/118/4/e2017225118
AM SURE Mugmods........u understand all of this.
Copy and Paste, hoping u have the correct part! Gawd.....